奶粉召回风波中的嘉必优收到监管工作函，奶粉企业纷纷撇清关系

Core Viewpoint - The incident involving the recall of infant formula by Nestlé due to potential quality risks associated with ARA raw materials from supplier Jabiou Biotechnology has raised significant concerns in the market, impacting the stock price of Jabiou and prompting regulatory scrutiny [1][2]. Group 1: Company Impact - Jabiou Biotechnology (Wuhan) Co., Ltd. received a regulatory notice from the Shanghai Stock Exchange urging timely responses and compliance with information disclosure obligations [1] - Following the recall announcement by Nestlé, Jabiou's stock price opened at 20.2 yuan, reflecting a decline of 1.22%, with a cumulative drop exceeding 16.7% since the incident [1] - Jabiou has stated that it has sent products for testing and will release results once available [1] Group 2: Industry Response - The State Council's Food Safety Office and the Market Supervision Administration emphasized the importance of Nestlé (China) fulfilling its corporate responsibilities and executing the recall of affected products sold in China [2] - Major domestic infant formula brands, including Yili, Mengniu, and others, have issued statements asserting the safety and reliability of their products, distancing themselves from the incident [2]